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Background: It is unclear whether smoking increases the risk of 
COVID-19 hospitalisation. We first examined the association of 
smoking status with hospitalisation for COVID-19 compared with 
hospitalisation for other respiratory viral infections a year previous. 
Second, we examined the concordance between smoking status 
recorded on the electronic health record (EHR) and the 
contemporaneous medical notes. 
Methods: This case-control study enrolled adult patients (446 cases 
and 211 controls) at a single National Health Service trust in London, 
UK. The outcome variable was type of hospitalisation (COVID-19 vs. 
another respiratory virus a year previous). The exposure variable was 
smoking status (never/former/current smoker). Logistic regression 
analyses adjusted for age, sex, socioeconomic position and 
comorbidities were performed. The study protocol and analyses were 
pre-registered in April 2020 on the Open Science Framework. 
Results: Current smokers had lower odds of being hospitalised with 
COVID-19 compared with other respiratory viruses a year previous 
(ORadj=0.55, 95% CI=0.31-0.96, p=.04). There was no significant 
association among former smokers (ORadj=1.08, 95% CI=0.72-1.65, p
=.70). Smoking status recorded on the EHR (compared with the 
contemporaneous medical notes) was incorrectly recorded for 168 
(79.6%) controls (χ2(3)=256.5, p=<0.001) and 60 cases (13.5%) (χ2
(3)=34.2, p=<0.001). 
Conclusions: In a single UK hospital trust, current smokers had 
reduced odds of being hospitalised with COVID-19 compared with 
other respiratory viruses a year previous, although it is unclear 
whether this association is causal. Targeted post-discharge recording 
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of smoking status may account for the greater EHR-medical notes 
concordance observed in cases compared with controls.
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Introduction
COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. There are in excess of 118 million confirmed
COVID-19 cases globally, with over 2.6 million deaths reported (Johns Hopkins Coronavirus Resource Center, 2021).
Large age and sex differences in case severity and mortality have been observed (Guan et al., 2020), with hypertension,
diabetes and obesity identified as important risk factors (Fang et al., 2020). There are a priori reasons to believe that
current smokers are at increased risk of contracting COVID-19 and experiencing greater disease severity once infected.
SARS-CoV-2 enters epithelial cells through the ACE-2 receptor (Hoffmann et al., 2020). Evidence suggests that gene
expression and subsequent ACE-2 receptor levels are elevated in the airway and oral epithelium of current smokers
(Brake et al., 2020; Cai, 2020), potentially making smokers vulnerable to contracting SARS-CoV-2. Other studies,
however, show that smoking downregulates the ACE-2 receptor (Oakes et al., 2018). In addition, smoking involves
repeated hand-to-mouthmovements, whichmaymean that smokers aremore likely to contract respiratory viruses such as
SARS-CoV-2 (Simons et al., 2020). Early data from the ongoing pandemic have not provided clear evidence for an
association of smoking status with COVID-19 outcomes, with a living review and unadjusted Bayesian meta-analysis of
over 60 studies indicating that current smokers, compared with those who had never smoked, may be at reduced risk of
SARS-CoV-2 infection, while former smokers are at increased risk of hospitalisation, disease severity and in-hospital
mortality compared with those who had never smoked (Simons et al., 2021).
Most studies to date have been limited by the lack of appropriate controls, poor recording of smoking status
and insufficient adjustment for relevant covariates. Many studies relied on routine electronic health records (EHRs) to
obtain data on demographic characteristics, comorbidities and smoking status. This is problematic, as previous research
suggests that data on smoking status obtained via EHRs tend to be incomplete or inaccurate, with implausible longitudinal
changes observed (Polubriaginof et al., 2018). As hospitalised populations differ by age and sex from the general
population (Secondary Care Analytical Team, 2020), comparisons of current and former smoking prevalence in
hospitalised and non-hospitalised populations are likely biased. There is therefore a need for alternative study designs
with relevant comparator groups and adjustment for covariates to better understand the association of smoking status with
COVID-19 disease outcomes.
However, the selection of an appropriate comparator group is not straightforward. Ideally, controls should represent the
underlying population fromwhich cases emerged, both geographically and demographically (Grimes and Schulz, 2005).
In the context of COVID-19 hospitalisation, disease severity and death, we therefore reasoned a priori that historical
controls – i.e. patients hospitalised at the same trust with another respiratory viral infection (e.g. influenza) a year previous
–would act as a useful comparator, as they represent a geographically matched population at risk of severe disease from a
circulating respiratory virus with a similar route of transmission (i.e. respiratory droplets and aerosols) and detection
(i.e. laboratory-confirmed infection prior to or upon hospitalisation) (McCarthy and Giesecke, 1999). In addition, risk
factors for hospitalisation with other respiratory viruses are similar to those for hospitalisation with COVID-19 (e.g. older
age, comorbidities) (Falsey et al., 2014; Peralta et al., 2010).
In the present case-control study, we therefore first aimed to examine the association of smoking status with hospitalisa-
tion for COVID-19 compared with hospitalisation for other respiratory viral infections (e.g. influenza, respiratory
syncytial virus) a year previous at a single UK hospital trust. Second, we aimed to examine whether there is a discordance
between smoking status recorded on the summary EHR and within the contemporaneous medical notes. As current
smoking in April 2020 (when our study protocol was registered) was a priori expected to be associated with an increased
risk of COVID-19 hospitalisation (Alqahtani et al., 2020; Simons et al., 2020), and with the association expected to be of
a similar magnitude to that observed for other respiratory viruses, we opted for a non-inferiority design to test the
hypothesis that the proportion of current smokers in patients hospitalised with COVID-19 is similar to that in patients
hospitalised with other respiratory viral infections a year previous.
Methods
Ethics statement
This study was approved by the UCL/UCLH Joint Research Office Research Strategy Group and UCLH Data Access
Committee. Approval to conduct research limited to pseudonymised patient data was provided by the NHS Health
Research Authority (IRAS_282704). The requirement for informed consent was waived by the NHS Health Research
Authority due to the observational nature of the study.
Study design
This was an observational case-control study with historical controls, performed at a single National Health Service
(NHS) hospital trust (comprising two hospital sites) in London, UK. The study protocol and analysis plan were pre-
registered on the Open Science Framework in April 2020 (Simons et al., 2020). The pre-registered protocol stipulated a
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non-inferiority design (i.e. a one-tailed statistical test) to maximise statistical power to detect a significantly lower
proportion of current smokers (i.e. <10%) among patients hospitalised with COVID-19 compared with patients
hospitalised with another respiratory viral infection a year previous (i.e. 20%). The protocol was amended after data
collection but prior to statistical analysis in September 2020 to implement a traditional case-control design (i.e. a two-
tailed statistical test), as a delay in study approval meant that the number of eligible cases and controls exceeded our
expectations; providing sufficient power for a two-tailed test. We had also planned to compare current smoking in cases
with age- and sex-matched London prevalence, with data obtained from the representative Annual Population Survey.
However, following an external review on an earlier manuscript draft, we decided against presenting data from this
comparison due to smoking rates in hospitalised populations typically being greater than in the general population
(Benowitz et al., 2009).
A sample size calculation, updated after data collection but prior to data analysis, indicated that 363 cases and
109 controls would provide 80% power to detect a 10% difference in current smoking prevalence in cases compared
with controls (e.g. 10% in cases and 20% in controls) with alpha set to 5%. We included all cases from 1st March 2020





1. Consecutive patients admitted to an adult hospital ward (i.e. 18+ years) between 1stMarch 2020 and 26th August
2020 (the date on which data were obtained).
2. Diagnosis of COVID-19 on or within five days of hospital admission, identified via associated International
Classification of Diseases version 10 (ICD-10) codes (World Health Organisation, 2019). This temporal
boundary was set to prevent inclusion of patents with nosocomial (hospital-acquired) infection and allowed
for a delay of three days in requesting a COVID-19 test and two days for receiving and reporting the results
on the EHR. The median incubation time for COVID-19 is estimated at 5.1 days (95% CI = 4.5-5.8) (Lauer
et al., 2020). We sought to exclude individuals with nosocomial COVID-19 infection as they are a different
population (e.g. older, more frail) compared with those infected in the community and subsequently requiring
hospitalisation.
Controls
1. Consecutive patients admitted to an adult hospital ward (i.e. 18+ years) between 1st January 2019 and
31st December 2019.
2. Diagnosis of a viral respiratory infection (e.g. influenza, parainfluenza) on or within 5 days of admission,
identified via ICD-10 codes.
Exclusion criteria
1. No record of smoking status on the summary EHR or within the medical notes.
2. A primary diagnosis of infectious exacerbation of chronic obstructive pulmonary disease (COPD) due to the
strong causal association of COPD with current and former smoking.
Measures
Data on demographic and smoking characteristics were collected from the summary EHRor themedical notes. In theUK,
the summary EHR is produced at the point of an individual's first interaction with a specific NHS hospital trust. Further
information is added to the summary EHR following subsequent interactions with the hospital trust. The medical notes
include contemporaneous clinical notes, General Practitioner referral letters and outpatient clinic letters, and are updated
more frequently than the summary EHR.
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Outcome variable
The outcome of interest was the type of hospital admission (i.e. with COVID-19 vs. other respiratory viral infections a
year previous).
Exposure variable
Smoking status (i.e. current, former, never) was obtained from the summary EHRor themedical notes. A number of cases
were recorded as ‘non-smokers’without distinguishing between ‘former smokers’ and ‘never smokers’. For the primary
analysis, patients categorised as a ‘non-smoker’ were treated as ‘never smokers’. Where possible, information on use of
smokeless tobacco, waterpipe and/or alternative nicotine products (e.g. e-cigarettes) was extracted. We searched within
the contemporaneous medical records for free-text entries of smoking status. The most recently available record of
smoking status, obtained from either the summary EHR or the medical notes, was extracted. Where available, data on
pack-year history of smoking (i.e. the number of packs of cigarettes smoked per day multiplied by the number of years of
smoking, with a pack equal to 20 cigarettes) were extracted.
Covariates
Covariates included age, sex, ethnicity, socioeconomic position (SEP; with post codes linked by the research team to the
Index of Multiple Deprivation (IMD) (Department for Communities and Local Government, 2019)) and comorbidities
(classified by organ system, including cardiac, metabolic and respiratory diseases).Medical conditions not expected to be
strongly associated with COVID-19 hospitalisation were not considered in the analyses (e.g. sciatica and fibromyalgia;
see Extended data). Age was treated as a continuous variable in the primary analysis, with banded age groups (i.e. 18-29
years, 30-44 years, 45-59 years, 60-74 years, 75-89 years and > 90 years) used in exploratory analyses. The IMD was
categorised as quintiles to reduce the impact of sparse data.
Data analysis
All analyses were conducted in R version 4.0.2. (R Core Team, 2020). Descriptive statistics for cases and controls are
reported. To explore differences between cases and controls, Pearson’s Chi-square tests, Cochran-Armitage tests for
trend and ANOVAs were used, as appropriate.
To examine the association of former and current smoking with hospitalisation for COVID-19 compared with
hospitalisation for other respiratory viral infections, unadjusted and two different adjusted generalised linear models
with a binomial distribution and logit link function were performed. The first model adjusted for age, sex and SEP, with
a second model adjusting for age, sex, SEP and comorbidities. We report odds ratios (ORs), 95% confidence intervals
(CIs) and p-values. Two sensitivity analyses were subsequently performed. First, those recorded as ‘non-smokers’ were
removed from the analysis. Second, those excluded from the analytic sample due to missing data on smoking status (see
section above on ‘Exclusion criteria’) were included and coded as i) ‘never smokers’ and then as ii) ‘current smokers’ to
assess the robustness of the associations.
To examine the concordance between smoking status recorded on the summary EHR and within the contemporaneous
medical notes, Pearson’s Chi-squared tests were performed for the entire sample, and then separately for cases and
controls.
Results
A total of 610 potential cases and 514 potential controls were identified. A total of 446 cases and 211 controls were
included in the analytic sample (see Figure 1). In total, 13 potential controls and 60 potential cases were excluded due to
not having a record of documented smoking status. This was likely due to patients having no prior contact with the NHS
foundation trust. Notably, 37 (62%) potential cases that were excluded because of missing smoking status did not survive
to hospital discharge, with no in-hospital mortality in potential controls, which suggests that data may be missing due to
increased mortality in cases.
Compared with controls, cases were more likely to be male (55% vs. 35.9%) and older (64.9 years vs 62.5 years) (see
Table 1). Approximately 10% of cases and controls had missing data for ethnicity. Compared with cases, controls were
more likely to be admitted from more deprived areas (IMD quintiles 1 and 2) (41.8% vs. 32.9%, p < 0.001). Cases were
more likely than controls to have pre-existing metabolic (30.3% vs 13.3%) and cardiac comorbidities (53.4% vs 30.3%).
A significantly larger proportion of cases compared with controls did not survive to discharge (28.7% vs. 4.3%). Among
128 cases not surviving to discharge, 53 (41.4%) were never smokers, 63 (49.2%) were former smokers and 12 (9.4%)
were current smokers. For patients who survived to discharge, the median length of hospital stay for cases and controls
was 9 (IQR = 4-18) and 4 (IQR = 2-9) days, respectively (see Table 1).
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Cases and controls were predominantly admitted from North central and North East central London (see Extended data,
Figure S1). The number of cases admitted from peripheral locations was greater than in controls and represents transfer of
inpatients from other hospitals and diversion of patients that would otherwise have attended local hospitals due to bed
pressures. The Chi-square test for trend found inconclusive evidence for any difference in SEP between cases and
controls, χ2(3) = 8.93, p = 0.06 (see Extended data).
Association of smoking status with type of hospitalisation
The prevalence of former smoking was higher in cases compared with controls (38.6% vs. 31.8%). Current smoking
prevalence was lower in cases compared with controls (9.4% vs. 17.1%). A single patient from the case cohort was
recorded as a dual cigarette and e-cigarette user. Two patients, one from each cohort, were recorded as dual cigarette and
shisha/waterpipe users. Pack-year history of smoking was only recorded for 40% of patients with a smoking history (see
Table 1).
In the univariable analysis, current smokers had reduced odds of being hospitalised with COVID-19 compared with other
respiratory viruses a year previous (OR = 0.52, 95% CI = 0.31-0.86, p = 0.01). The odds for former smokers were
equivocal (OR = 1.16, 95% CI = 0.81-1.68, p = 0.43).
In the multivariable analysis adjusted for sex, age and SEP, current smokers had reduced odds of being hospitalised with
COVID-19 comparedwith other respiratory viruses a year previous (OR=0.48, 95%CI = 0.28-0.83, p< 0.01). Therewas
no significant association among former smokers (OR = 0.90, 95%CI = 0.61-1.34, p = 0.61). Results were not materially
altered when also adjusting for relevant comorbidities (current smokers, OR = 0.55, 95%CI = 0.31-0.96, p = 0.04; former
smokers, OR = 1.08, 95% CI = 0.72-1.61, p = 0.70).
Sensitivity analyses
First, in a sensitivity analysis with patients recorded as ‘non-smokers’ excluded from the sample (leaving 398 cases and
159 controls), current smokers had reduced odds of being hospitalised with COVID-19 compared with other respiratory
viruses a year previous (OR = 0.41, 95% CI = 0.22-0.74, p = 0.03). There was no significant association among former
smokers (OR = 0.78, 95% C.I. = 0.49-1.23, p = 0.28).
Figure 1. Eligibility flow diagram for controls (left hand side) and cases (right hand side).
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Female sex 116 (55.0%) 160 (35.9%) 276 (42.0%) <0.001
Age in years (continuous) 0.019
- Median (IQR) 62.5 (48.5-75.8) 64.9 (52.4-76.2) 64.58 (51.3-76.1)
Age in years (banded) 0.007
- 18-29 18 (8.5%) 11 (2.5%) 29 (4.4%)
- 30-44 22 (10.4%) 37 (8.3%) 59 (9.0%)
- 45-59 46 (21.8%) 113 (25.3%) 159 (24.2%)
- 60-74 67 (31.8%) 162 (36.3%) 229 (34.9%)
- 75+ 58 (27.5%) 123 (27.6%) 181 (27.5%)
Ethnicity 0.243
- Black British, Black African or Black
Caribbean
19 (9.0%) 63 (14.1%) 82 (12.5%)
- White British or White Other 116 (55.0%) 220 (49.3%) 336 (51.1%)
- Not stated 26 (12.3%) 43 (9.6%) 69 (10.5%)
- Asian British or Asian 28 (13.3%) 68 (15.2%) 96 (14.6%)
- Other 22 (10.4%) 52 (11.7%) 74 (11.3%)
IMD quintile 0.06
- Missinga 5 (2.4%) 5 (1.1%) 10 (1.5%)
- 1 - Most deprived 21 (10.0%) 26 (5.8%) 47 (7.2%)
- 2 67 (31.8%) 121 (27.1%) 188 (28.6%)
- 3 42 (19.9%) 122 (27.4%) 164 (25.0%)
- 4 38 (18.0%) 98 (22.0%) 136 (20.7%)
- 5 - Least deprived 38 (18.0%) 74 (16.6%) 112 (17.0%)
Most recent record of smoking status
(summary EHR or medical notes)
0.012
- Never smoker 108 (51.2%) 232 (52.0%) 340 (51.8%)
- Former smoker 67 (31.8%) 172 (38.6%) 239 (36.4%)
- Current smoker 36 (17.1%) 42 (9.4%) 78 (11.9%)
Record of pack-year smoking history in
former and current smokers
36 (35%) 91 (42.5%) 127 (40%)
- Pack-year smoking history in current
smokers, median (IQR)
30 (22.5-45) 30 (6-45) 30 (16.8-45.5)
- Pack-year smoking history in former
smokers, median (IQR)
20 (10-40) 25 (10-40) 25 (10-40)
Recorded smoking status on summary
EHR
<0.001
- Never smoker 23 (10.9%) 233 (52.2%) 256 (39.0%)
- Former smoker 22 (10.4%) 152 (34.1%) 174 (26.5%)
- Current smoker 7 (3.3%) 30 (6.7%) 37 (5.6%)
- Unknown 159 (75.4%) 31 (7.0%) 190 (28.9%)
Survival to discharge 202 (95.7%) 318 (71.3%) 520 (79.1%) <0.001
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Second, in a sensitivity analysis with those with missing data on smoking status (n = 73) treated as ‘never smokers’
(resulting in 506 cases and 224 controls), patients hospitalised with COVID-19 had reduced odds of being a current
smoker compared with those admitted with other respiratory viruses (OR = 0.51, 95% CI = 0.30-0.88, p = 0.01). Next,
when those with missing data on smoking status were treated as ‘current smokers’, there was no significant association









Length of hospital admission for
survivors (days)
<0.001
- Median (IQR) 4 (2-9) 9 (4-18) 7 (3-14)
Cancer (current or past) 66 (31.3%) 90 (20.2%) 156 (23.7%) 0.002
Auto-immune disease (present) 12 (5.7%) 16 (3.6%) 28 (4.3%) 0.213
Metabolic disease (present) 28 (13.3%) 135 (30.3%) 163 (24.8%) <0.001
Haematological disease (present) 3 (1.4%) 4 (0.9%) 7 (1.1%) 0.541
Cardiac disease (present) 64 (30.3%) 238 (53.4%) 302 (46.0%) <0.001
Neurological disease (present) 24 (11.4%) 54 (12.1%) 78 (11.9%) 0.786
Respiratory disease (present) 54 (25.6%) 91 (20.4%) 145 (22.1%) 0.134
Renal disease (present) 12 (5.7%) 37 (8.3%) 49 (7.5%) 0.235
HIV (present) 2 (0.9%) 7 (1.6%) 9 (1.4%) 0.522
No relevant comorbidities 43 (20.4%) 85 (19.1%) 128 (19.5%) 0.690
aIMD is not available for individuals with home addresses outside of England.
Figure 2. Concordance between smoking status recorded on the summary EHR and the medical notes for
controls (red) and cases (blue).
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Concordance of smoking status recorded on the summary EHR and the medical notes
Controls weremore likely to have no record of smoking status on the summary EHR comparedwith cases (75.4% vs. 7%)
(see Figure 2). However, smoking status could be ascertained from the contemporaneous medical notes for all included
cases and controls. Smoking status on the summary EHR (including ‘unknown’ status) was incorrectly recorded for
168 (79.6%) controls and 60 cases (13.5%) (χ2(3) = 226.7, p = < 0.001). In cases, six current smokers were misclassified
as former smokers, one current smoker as a never smoker and six current smokers had no record of smoking status on the
summary EHR. In controls, six current smokers were misclassified as former smokers and 23 current smokers had no
record of smoking status on the summary EHR. There was greater discordance between smoking status recorded on the
summary EHR and within the contemporaneous medical notes in controls (χ2(3) = 256.5, p = < 0.001) than in cases
(χ2(3) = 34.2, p = < 0.001).
Discussion
This observational case-control study with patients admitted to a single UK hospital trust found a lower proportion
of current smokers in cases hospitalised with COVID-19 during the first phase of the pandemic compared with controls
hospitalised with other respiratory viral infections a year previous. Further, we found that smoking status is typically
poorly recorded in the summary EHR. This was more prominent in controls than cases – a difference that is likely
explained by the observation that COVID-19 patients were followed up by the respiratory medicine team after discharge,
as part of a COVID-19 follow-up clinic where they specifically asked about smoking status (Mandal et al., 2020). The
observed discrepancy between smoking status recorded on summary EHRs and the contemporaneous medical notes is a
concern, particularly for studies relying solely on EHRs as the source of information on smoking status.
Strengths and limitations
To our knowledge, this is one of few studies specifically designed to examine the association between smoking status and
hospitalisation with COVID-19. It was further strengthened by an assessment of the quality of data on smoking status
gleaned from summary EHRs.
However, this study has several important limitations, the majority of which pertain to the selection of the controls. First,
current smoking is expected a priori to be associated with hospitalisation for non-COVID-19 respiratory viruses
(Stämpfli & Anderson, 2009). Ideally, hospital-based case-control studies should avoid selecting a control disease
which is associated with the exposure of interest (i.e. smoking status) (Vandenbroucke & Pearce, 2012). However, to our
knowledge, there is no other control disease with a similar route of acquisition and mechanism for hospitalisation/severe
disease that is not a priori also associatedwith smoking status. The greater smoking prevalence in controls comparedwith
the general population fromwhich the cases emerged (Vandenbroucke& Pearce, 2012) therefore likely contributes to the
significantly reduced odds of current smoking in our cases.
Second, the risk profile for controls likely differs from cases in that there is prior immunity to other respiratory viruses
(e.g. influenza, respiratory syncytial virus), with no prior immunity in the population to SARS-CoV-2.
Third, we selected the controls on the basis of sharing a similar route of transmission and risk factors for hospitalisation as
cases. However, at the time of writing (March 2021), we now suspect that COVID-19 differs from other respiratory
viruses in several ways. For example, COVID-19 gains cell entry via the ACE-2 receptor (Hoffmann et al., 2020), with
unknown receptor binding in flu (Killingley & Nguyen-Van-Tam, 2013) and appears to display less fomite and physical
contact transmission than flu (Ben-Shmuel et al., 2020). In addition, emerging evidence suggests that COVID-19 has
a significantly different pathological process compared with other respiratory viruses. For example, mortality rates
from COVID-19 differ widely from those due to epidemic influenza (Office for National Statistics, 2020a). Although we
currently do not know the importance of these factors, taken together, emerging observations may mean that direct
comparison of risk profiles in cases and controls is limited.
Fourth, while no known behavioural restrictions were implemented during the control period, London was under
lockdown restrictions from March to July 2020, which likely impacted the risk of viral exposure in cases (Davies
et al., 2020). Thismay further have impacted the different risk profiles of controls and cases beyond the adjustmentsmade
in this analysis for sex, age and SEP.
Fifth, the selection of historical controls may mean that there are non-trivial differences in smoking status between
controls and cases due to a declining trend in London smoking prevalence (Office for National Statistics, 2020b).
However, a single year was used for the selection of controls, and there was no large change in national smoking
prevalence from 2019 to 2020 in England (Brown, 2020), so we expect any impact of the time-varying exposure to be
minimal.We considered using a contemporaneous control (i.e. patients hospitalisedwith other respiratory viral infections
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in 2020), which would have mitigated against this potential bias. However, due to factors such as reduced national and
international travel, physical distancing, increased hand hygiene and potential viral dominance by COVID-19, exposure
to and hospitalisation with other respiratory viruses has been substantially reduced in 2020 (GOV.UK, 2020), which
would have limited the sample size for controls.
Sixth, a history of current or past cancer was high in both groups at greater than 20% and was significantly greater in
controls compared with cases. This reflects a bias in the population that regularly interacts with the selected NHS hospital
trust, which is a specialist cancer referral centre.We visualised the geographic regions where patients were admitted from
to examine any systemic differences between cases and controls, and caution that the differing catchment areas of the two
cohorts may have led to important differences in the underlying populations. In addition, during the peak of the first wave
of the pandemic in the UK (i.e. March-April 2020), many cases were transferred across hospital sites due to bed pressures
(Dunhill, 2020).
Finally, there was a greater proportion of cases than controls with no record of smoking status on either the summary EHR
or within the contemporaneous medical notes (thus, they were not eligible for inclusion), with patients with missing data
having unusually highmortality. It is plausible that many of themwere smokers.We attempted to mitigate against this by
conducting several sensitivity analyses, with the results largely remaining robust. However, when those excluded from
the cohort due to missing data on smoking status were treated as current smokers, there was no significant association
between current smoking and hospitalisation for COVID-19.
Despite these limitations, alternative designs were impracticable or would have had different limitations. In the future, the
current study can be considered alongside findings across multiple such alternative methodological approaches, each
with different sources of bias, to triangulate on the extent to which associations between smoking and COVID-19 are
causal.
Implications for policy and practice
COVID-19 will continue to place a large burden on healthcare services in the UK and internationally over the coming
months and years. To mitigate against this, multiple non-pharmacological interventions are being implemented to reduce
the intensity of demand on acute and intensive services. Irrespective of any direct link between smoking and COVID-19
disease outcomes, smoking is a significant cause for healthcare demand globally.We have argued elsewhere for the need
to ramp up smoking cessation support to reduce the current and future burden on healthcare and social services (Simons
et al., 2020).
Avenues for future research
The selection of appropriate controls in hospital-based case-control studies is very challenging for a novel respiratory
virus such as COVID-19 (which means we converged on a hybrid approach, combining elements from hospital-based
case series and case-control designs with historical controls).We recommend the use of representative population-studies
with data from multiple sites and with purposeful acquisition of smoking status, to better understand the role of smoking
as a potential risk or protective factor for COVID-19 hospitalisation and disease severity.
Conclusion
In a single hospital trust in the UK, current smokers had reduced odds of being hospitalised with COVID-19 compared
with other respiratory viruses a year previous, although we caution against interpreting this as a causal association.
Smoking status was poorly recorded, with high observed discordance between smoking status recorded on the summary
EHR and the contemporaneous medical notes.
Data availability
Underlying data
Due to the sensitive nature of the data, we do not have ethical approval to release the individual-level data underpinning
the analyses. Anonymised and de-identified individual-level data are available upon request from the corresponding
author to bona fide researchers and following approval from the Biomedical Research Centre Clinical and Research
Informatics Unit at University College London Hospital NHS foundation trust.
Extended data
OSF: Association of smoking status with hospitalisation for COVID-19 compared with other respiratory viruses a year
previous: a case-control study at a single UK National Health Service trust: Protocol. https://doi.org/10.17605/OSF.
IO/84VYD (Simons et al., 2021).
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This project contains the following extended data:
- Date file 1. (Extended data, PDF format)
- Data file 2. (Protocol, docx format)
Data are available under the terms of the Creative Commons Attribution 4.0 International (CC-By Attribution 4.0
International).
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This study's results amazed me. Other studies found a strong association between smoking and 
hospitalization from COVID-19. Interestingly, we found an association between current smoking 
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